BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

Bristol Myers Squibb helmsman Chris Boerner joined a growing list of life sciences leaders announcing major U.S. investments ...

In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing ...

The funds will reportedly be allocated for R&D, technology advancements, and enhancing domestic manufacturing capacity.

(Reuters) -Bristol Myers Squibb said on Monday it will invest $40 billion in the U.S. over the next five years, as it seeks ...

He will be replaced as CEO by Christopher Boerner, currently head of commercialisation at the group, who will prepare for the top job with an immediate move to the role of chief operating officer.

“It’s important to remember there are no currently approved adjunctive therapies for schizophrenia,” Boerner added on the company’s call. “Our commercial strategy remains focused on ...

CEO Chris Boerner highlighted a strong start to 2025 with $11.2 billion in total revenue, driven by 18% growth in the company's growth portfolio. Key contributors included the I-O portfolio ...

(Reuters) -Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in ...